MedTrace Logo

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

NCT01045369 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-05-01

No results posted yet for this study

Summary

The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood. Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.

Conditions

  • HIV Infections

Interventions

DRUG

Kaletra and Intelence Tablets

Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Tibotec, Inc

    collaborator INDUSTRY

  • BluKyne

    collaborator UNKNOWN

  • Therapeutic Concepts

    lead OTHER

Principal Investigators

  • Joseph C. Gathe, Jr., MD · Therapeutic Concepts

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-04-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01045369 on ClinicalTrials.gov